Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 16, 2025Future Medicinal Chemistry

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMd Sadique HussainLZL. ZhangARAmita Joshi Rana

Discussion

Loading...

Member takes

Overview

Review explores novel HDAC-PROTACs in cancer therapy, highlighting treatment efficacy and selectivity challenges.

Key Points

  • HDAC-PROTACs provide a new strategy for cancer treatment by degrading HDACs through the ubiquitin-proteasome system.
  • Unlike traditional inhibitors, PROTACs need lower dosages while maintaining prolonged therapeutic effects in cancer models.
  • Advancements in PROTAC chemistry enable selective targeting of distinct HDAC classes with notable anti-cancer activity.
  • Despite progress, optimizing selectivity and enhancing bioavailability remain challenges for clinical applications.

Cite This Study

Hussain et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccc5ehttps://doi.org/10.1080/17568919.2025.2533113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  2. 2Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025
  3. 3Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation2025 · 11 citations
  4. 4Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death2025 · 4 citations
  5. 5Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy2025